SATB1 and neoplasm: To assess clinical relevance, we analyzed HCC patient data (GSE111389) and observed consistent SATB1 downregulation in PD-1 high (PD-1 hi) tumor-infiltrating CD8+ T cells across all six patients (Fig. S1C) [36].